1
|
Destruel PL, Zeng N, Brignole-Baudouin F, Douat S, Seguin J, Olivier E, Dutot M, Rat P, Dufaÿ S, Dufaÿ-Wojcicki A, Maury M, Mignet N, Boudy V. In Situ Gelling Ophthalmic Drug Delivery System for the Optimization of Diagnostic and Preoperative Mydriasis: In Vitro Drug Release, Cytotoxicity and Mydriasis Pharmacodynamics. Pharmaceutics 2020; 12:E360. [PMID: 32326492 PMCID: PMC7238180 DOI: 10.3390/pharmaceutics12040360] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 04/08/2020] [Accepted: 04/13/2020] [Indexed: 11/16/2022] Open
Abstract
Mydriasis is required prior to many eye examinations and ophthalmic surgeries. Nowadays, phenylephrine hydrochloride (PHE) and tropicamide (TPC) are extensively used to induce mydriasis. Several pharmaceutic dosage forms of these two active ingredients have been described. However, no optimal therapeutic strategy has reached the market. The present work focuses on the formulation and evaluation of a mucoadhesive ion-activated in situ gelling delivery system based on gellan gum and hydroxyethylcellulose (HEC) for the delivery of phenylephrine and tropicamide. First, in vitro drug release was studied to assess appropriate sustained drug delivery on the ocular surface region. Drug release mechanisms were explored and explained using mathematical modeling. Then, in situ gelling delivery systems were visualized using scanning electron microscopy illustrating the drug release phenomena involved. Afterward, cytotoxicity of the developed formulations was studied and compared with those of commercially available eye drops. Human epithelial corneal cells were used. Finally, mydriasis intensity and kinetic was investigated in vivo. Mydriasis pharmacodynamics was studied by non-invasive optical imaging on vigilant rabbits, allowing eye blinking and nasolacrimal drainage to occur physiologically. In situ gelling delivery systems mydriasis profiles exhibited a significant increase of intensity and duration compared with those of conventional eye drops. Efficient mydriasis was achieved following the administration of a single drop of in situ gel reducing the required amount of administered active ingredients by four- to eight-fold compared with classic eye drop regimen.
Collapse
Affiliation(s)
- Pierre-Louis Destruel
- Unither Développement Bordeaux, ZA Tech Espace, av Toussaint Catros, 33185 Le Haillan, France;
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| | - Ni Zeng
- Unither Pharmaceuticals, 3-5 rue St-Georges, 75009 Paris, France
| | - Françoise Brignole-Baudouin
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
- CNRS UMR 7210-Inserm UMR_S 968, Institut de la Vision, 75012 Paris, France
- Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, INSERM-DHOS, CIC 503, 75012 Paris, France
| | - Sophie Douat
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
| | - Johanne Seguin
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| | - Elodie Olivier
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
| | - Melody Dutot
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
- Recherche et Développement, Laboratoire d’Evaluation Physiologique, Yslab, 2 rue Félix le Dantec, 29000 Quimper, France
| | - Patrice Rat
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
| | - Sophie Dufaÿ
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
| | - Amélie Dufaÿ-Wojcicki
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
| | - Marc Maury
- Unither Pharmaceuticals, 3-5 rue St-Georges, 75009 Paris, France
| | - Nathalie Mignet
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| | - Vincent Boudy
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| |
Collapse
|
2
|
Destruel PL, Zeng N, Seguin J, Douat S, Rosa F, Brignole-Baudouin F, Dufaÿ S, Dufaÿ-Wojcicki A, Maury M, Mignet N, Boudy V. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time. Int J Pharm 2019; 574:118734. [PMID: 31705970 DOI: 10.1016/j.ijpharm.2019.118734] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 09/20/2019] [Accepted: 09/24/2019] [Indexed: 12/15/2022]
Abstract
Achieving drug delivery at the ocular level encounters many challenges and obstacles. In situ gelling delivery systems are now widely used for topical ocular administration and recognized as a promising strategy to improve the treatment of a wide range of ocular diseases. The present work describes the formulation and evaluation of a mucoadhesive and ion-activated in situ gelling delivery system based on gellan gum and hydroxyethylcellulose for the delivery of phenylephrine and tropicamide. First, physico-chemical characteristics were assessed to ensure suitable properties regarding ocular administration. Then, rheological properties such as viscosity and gelation capacity were determined. Gelation capacity of the formulations and the effect of hydroxyethylcellulose on viscosity were demonstrated. A new rheological method was developed to assess the gel resistance under simulated eye blinking. Afterward, mucoadhesion was evaluated using tensile strength test and rheological synergism method in both rotational and oscillatory mode allowing mucoadhesive properties of hydroxyethylcellulose to be point out. Finally, residence time on the ocular surface was investigated in vivo, using cyanine 5.5 dye as a fluorescent marker entrapped in the in situ gelling delivery systems. Residence performance was studied by non-invasive optical imaging on vigilant rabbits, allowing eye blinking and nasolacrimal drainage to occur physiologically. Fluorescence intensity profiles pointed out a prolonged residence time on the ocular surface region for the developed formulations compared to conventional eye drops, suggesting in vitro / in vivo correlations between rheological properties and in vivo residence performances.
Collapse
Affiliation(s)
- Pierre-Louis Destruel
- Unither Développement Bordeaux, ZA Tech Espace, av Toussaint Catros, Le Haillan 33185, France; Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France; Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1)
| | - Ni Zeng
- Unither Pharmaceuticals, 3-5 rue St-Georges, Paris 75009, France
| | - Johanne Seguin
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1)
| | - Sophie Douat
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Frédéric Rosa
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Françoise Brignole-Baudouin
- UMR CNRS 8638 - Chimie Toxicologie Analytique et Cellulaire, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 4 Avenue de l'Observatoire, Paris 75006, France; CNRS UMR 7210 - Inserm UMR_S 968, Institut de la Vision, Paris, 75012, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DHOS, CIC 503, Paris, 75012, France
| | - Sophie Dufaÿ
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Amélie Dufaÿ-Wojcicki
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Marc Maury
- Unither Pharmaceuticals, 3-5 rue St-Georges, Paris 75009, France
| | - Nathalie Mignet
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1)
| | - Vincent Boudy
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France; Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1).
| |
Collapse
|